Skip Navigation
Menu
ACP Journal Club |16 December 2008

A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes

Arsh K. Jain, MD; Matthew A. Weir, MD

Article, Author, and Disclosure Information
FULL TEXT
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53. 18707986

Cardiology:

Nephrology:

The large multicenter ONTARGET trial by Mann and colleagues compared combination angiotensin-converting enzyme (ACE) inhibitor and angiotensin-receptor blocker (ARB) therapy with either drug alone for cardiovascular events in patients with coronary artery disease (CAD) or diabetes and ≥ 1 other risk factor for CAD. Combination therapy did not provide benefit over monotherapy for the composite of renal outcomes. As well, the ARB and ACE inhibitor...
FULL TEXT
PDF
Not Available
Citations
Citation

Jain AK, Weir MA. A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes. Ann Intern Med. 2008;149:JC6–7. doi: https://doi.org/10.7326/0003-4819-149-12-200812160-02007

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2008;149(12):JC6-7.

DOI: 10.7326/0003-4819-149-12-200812160-02007

0 Citations

Related Articles
NORMAL KIDNEYS AND RETINAE AFTER 35 YEARS OF DIABETES*
Annals of Internal Medicine; 47 (6): 1256-1259
THE RÔLE OF DIABETES IN THE DEVELOPMENT OF DEGENERATIVE VASCULAR DISEASE: WITH SPECIAL REFERENCE TO THE INCIDENCE OF RETINITIS AND PERIPHERAL NEURITIS*
Annals of Internal Medicine; 14 (10): 1893-1902
Effect of Telmisartan on Renal Outcomes: A Randomized Trial
Annals of Internal Medicine; 151 (1): 1-10
Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes
Annals of Internal Medicine; 146 (6): 461-463
View MoreView Less

Journal Club
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
Annals of Internal Medicine; 167 (12): JC66
Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes
Annals of Internal Medicine; 167 (2): JC5
TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with men
Annals of Internal Medicine; 164 (6): JC28
Adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events
Annals of Internal Medicine; 161 (10): JC8
View MoreView Less

Related Point of Care
Acute Kidney Injury
Annals of Internal Medicine; 167 (9): ITC66-ITC80
View MoreView Less

Related Topics
Cardiology
Coronary Risk Factors
Diabetes
Endocrine and Metabolism
Hypertension

Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Hypertension.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×